FyoniBio
Tailor-made Biopharma Development

Press Release

Berlin, 6. November 2026: FyoniBio GmbH and Mabion S.A. have executed a letter of intent (LoI) to establish a close cooperation for providing integrated services regarding cell line development and the production of biologics for third-party clients

FyoniBio GmbH, a German globally leading specialist in cell line and processes development and Mabion S.A. (WSE: MAB), a Polish biotechnology company specializing in the development and production of biological products have signed LoI to provide integrated solutions for the provision of biologics.
This synergistic partnership enables the creation of a unique, complementary offering for the global biotechnology market. A main aim of the parties is to jointly provide contract development and manufacturing services for the Japanese market, one of the world's largest pharmaceutical markets.

The parties have outlined the potential and responsibilities in broad terms in acquiring and implementing joint customer projects.
Whereas FyoniBio will provide services regarding cell line development and upstream processes.
Whereas Mabion will provide services regarding the master cell banking, downstream processes, production drug substances and drug products.

"We are very pleased partnering with Mabion to synergistically deliver biologics in high yield and stellar quality. FyoniBio's industry spearheading CHOnamite® and CHOFlow® platforms will feed seamlessly into Mabion's state of the GMP manufacturing sites. Besides the technological fit, we share the same passion and drive to develop therapeutics as our colleagues at Mabion" - states Dr. Lars Stöckl, Managing Director of FyoniBio.

"By combining the strengths, expertise, and technologies of both companies, we can deliver greater value to our customers, respond faster to market changes, and turn new opportunities into real business results. We look for partners who share our ambition, understand the pace of the market, and are focused on delivering results. From our very first meeting, we felt that we shared the same energy and vision. I'm confident that this partnership brings together the right capabilities and mindset to create new opportunities, drive growth, and deliver lasting success." comments Detlef Behrens, Chief Business Affairs Officer of Mabion S.A.

The parties intend to formalize enter into a long-term framework agreement.

Information about FyoniBio GmbH

FyoniBio is a biologics service provider with over 15 years of scientific expertise and a proven track record of supporting more than 100 biologics projects for biotech and pharma companies worldwide. Trusted by partners whose products have reached clinical development in both FDA and EMA regions, FyoniBio offers a broad service portfolio covering the entire development chain — from cell line and process development to analytical characterization and clinical bioanalysis under GCLP.

Our team combines deep scientific understanding with flexibility and transparent communication to deliver tailored solutions that meet each project's specific needs. All services are performed under our ISO 9001–certified quality management system, ensuring full compliance with international ISO and ICH standards. Learn more at: www.fyonibio.com

Information about Mabion S.A.

Mabion S.A. (WSE:MAB) is a Polish biopharmaceutical company founded in 2007, which in 2023–2024 transformed into a CDMO (Contract Development and Manufacturing Organization) specializing in biotechnology and offering an integrated range of services. Mabion offers a wide range of services for small and medium-sized projects at various stages of development (from R&D work involving the creation of stable cell lines to commercial-scale production). Mabion's key competencies include technologies for the development of monoclonal antibodies and other recombinant proteins (produced using mammalian and insect cell systems), advanced analytics, and the manufacture of active pharmaceutical ingredients (Drug Substance). The company operates in accordance with internationally recognized quality standards, including GMP, GCP, and ISO. Mabion employs nearly 200 highly qualified specialists, including scientists, engineers, and experts in quality, manufacturing, and the development of analytical methods for biological products. Headquartered in the heart of Europe, Mabion operates in Poland—an EU member state—providing access to highly regulated markets. The company's mission is to be a trusted global partner in the development and manufacture of biologics. Mabion is a publicly traded company listed on the Warsaw Stock Exchange. For more information: www.mabion.eu

Press Contacts

Abdullah Karacorluoglu
Business Development Manager, FyoniBio
abdullah.karacorluoglu@fyonibio.com

Aneta Filipczak
+48 530 979 039
Aneta.filipczak@corepr.pl